Viking Therapeutics to Participate in Upcoming Investor Conferences

News provided by

Sep 02, 2021, 16:05 ET

SAN DIEGO, Sept. 2, 2021 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will participate in four upcoming investor conferences.

Details of the company's participation are as follows:

Citi's 16^th Annual Biopharma Virtual Conference
Details: Viking management will participate in 1-on-1 meetings
Conference Dates: September 8-10, 2021
Format: Virtual conference

H.C. Wainwright 23^rd Annual Global Investment Conference
Details: Viking management will deliver a corporate presentation and participate in 1-on-1 meetings
Conference Dates: September 13-15, 2021
Presentation Timing: Available online at 7:00 a.m. Eastern on Monday, September 13, 2021
Format: Virtual conference

Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
Details: Viking management will deliver a corporate presentation and participate in 1-on-1 meetings
Conference Dates: September 20-23, 2021
Presentation Timing: Tuesday, September 21, 2021 at 2:55 p.m. Eastern
Format: Virtual conference, webcast available

Cantor Fitzgerald Virtual Global Healthcare Conference
Details: Viking management will deliver a corporate presentation and participate in 1-on-1 meetings
Conference Dates: September 27-30, 2021
Presentation Timing: Thursday, September 30, 2021 at 2:00 p.m. Eastern
Format: Virtual conference

A webcast of the Oppenheimer presentation may be accessed via a link on the Viking Therapeutics website in the Investors & Media section under Webcasts. Additionally, a replay of the webcast will be available on the Viking website following the conferences.

About Viking Therapeutics, Inc.

Viking Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel, orally available, first-in-class or best-in-class therapies for the treatment of metabolic and endocrine disorders. Viking's research and development activities leverage its expertise in metabolism to develop innovative therapeutics designed to improve patients' lives. The company's clinical programs include VK2809, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders, which is currently being evaluated in a Phase 2b study for the treatment of biopsy-confirmed non-alcoholic steatohepatitis (NASH) and fibrosis. In a Phase 2a trial for the treatment of non-alcoholic fatty liver disease (NAFLD) and elevated LDL-C, patients who received VK2809 demonstrated statistically significant reductions in LDL-C and liver fat content compared with patients who received placebo. The company is also developing VK0214, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the potential treatment of X-linked adrenoleukodystrophy (X-ALD). VK0214 is currently being evaluated in a Phase 1b clinical trial in patients with the adrenomyeloneuropathy (AMN) form of X-ALD. The company holds exclusive worldwide rights to a portfolio of five therapeutic programs, including those noted above, which are based on small molecules licensed from Ligand Pharmaceuticals Incorporated.

For more information about Viking Therapeutics, please visit www.vikingtherapeutics.com. Follow Viking on Twitter @Viking_VKTX.

SOURCE Viking Therapeutics, Inc.